Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
27919 | 218 | 39.7 | 91% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
419 | 3 | ADENOVIRUS//MERKEL CELL CARCINOMA//GENE THERAPY | 28518 |
564 | 2 | GENE THERAPY//ADENOVIRUS//HUMAN GENE THERAPY | 14456 |
27919 | 1 | GENE THER Y SCI//RECOMBINANT SENDAI VIRUS//HVJ E | 218 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | GENE THER Y SCI | address | 744914 | 20% | 12% | 44 |
2 | RECOMBINANT SENDAI VIRUS | authKW | 720361 | 3% | 86% | 6 |
3 | HVJ E | authKW | 689572 | 4% | 62% | 8 |
4 | SENDAI VIRUS STRAIN TIANJIN | authKW | 560282 | 2% | 100% | 4 |
5 | SENDAI VIRUS | authKW | 460032 | 14% | 11% | 30 |
6 | HVJ | authKW | 457556 | 3% | 47% | 7 |
7 | CYTOPLASMIC RNA VECTOR | authKW | 420212 | 1% | 100% | 3 |
8 | INACTIVATED SENDAI VIRUS HVJ E | authKW | 420212 | 1% | 100% | 3 |
9 | SENDAI VIRUS VECTOR | authKW | 403725 | 3% | 41% | 7 |
10 | FUBP1 | authKW | 389081 | 2% | 56% | 5 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Medicine, Research & Experimental | 717 | 22% | 0% | 48 |
2 | Genetics & Heredity | 518 | 21% | 0% | 46 |
3 | Biotechnology & Applied Microbiology | 451 | 20% | 0% | 44 |
4 | Oncology | 415 | 24% | 0% | 52 |
5 | Biochemistry & Molecular Biology | 341 | 35% | 0% | 76 |
6 | Cell Biology | 280 | 20% | 0% | 43 |
7 | Virology | 78 | 5% | 0% | 11 |
8 | Cell & Tissue Engineering | 78 | 2% | 0% | 4 |
9 | Biophysics | 32 | 6% | 0% | 12 |
10 | Transplantation | 28 | 3% | 0% | 6 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GENE THER Y SCI | 744914 | 20% | 12% | 44 |
2 | CLIN GENET PROTE | 249010 | 2% | 44% | 4 |
3 | RD INNOVAT BIOTHER EUT | 214472 | 3% | 22% | 7 |
4 | PROTEOME PROJECT | 186759 | 1% | 67% | 2 |
5 | VIRAL INFECT VACCINE CONTROL | 186759 | 1% | 67% | 2 |
6 | 21 CENTURY COE PROGRAMCHUO KU | 140071 | 0% | 100% | 1 |
7 | ABT VIRUSFO | 140071 | 0% | 100% | 1 |
8 | CENTURY COE PROGRAM 21CHUO KU | 140071 | 0% | 100% | 1 |
9 | FIELDS TISSUE ENGN FRONTIER MED SCI | 140071 | 0% | 100% | 1 |
10 | FIELS TISSUE ENGN FRONTIER MED SCI | 140071 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GENE THERAPY | 10335 | 8% | 0% | 17 |
2 | JOURNAL OF GENE MEDICINE | 3580 | 3% | 0% | 6 |
3 | CURRENT GENE THERAPY | 2294 | 1% | 1% | 3 |
4 | NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES A, LIFE SCIENCES | 1557 | 1% | 1% | 2 |
5 | MOLECULAR THERAPY | 1414 | 3% | 0% | 6 |
6 | CANCER SCIENCE | 987 | 2% | 0% | 5 |
7 | FRONTIERS IN BIOSCIENCE-LANDMARK | 973 | 2% | 0% | 5 |
8 | CELL TRANSPLANTATION | 837 | 2% | 0% | 4 |
9 | MOLECULAR UROLOGY | 798 | 0% | 1% | 1 |
10 | HUMAN GENE THERAPY | 666 | 2% | 0% | 4 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | RECOMBINANT SENDAI VIRUS | 720361 | 3% | 86% | 6 | Search RECOMBINANT+SENDAI+VIRUS | Search RECOMBINANT+SENDAI+VIRUS |
2 | HVJ E | 689572 | 4% | 62% | 8 | Search HVJ+E | Search HVJ+E |
3 | SENDAI VIRUS STRAIN TIANJIN | 560282 | 2% | 100% | 4 | Search SENDAI+VIRUS+STRAIN+TIANJIN | Search SENDAI+VIRUS+STRAIN+TIANJIN |
4 | SENDAI VIRUS | 460032 | 14% | 11% | 30 | Search SENDAI+VIRUS | Search SENDAI+VIRUS |
5 | HVJ | 457556 | 3% | 47% | 7 | Search HVJ | Search HVJ |
6 | CYTOPLASMIC RNA VECTOR | 420212 | 1% | 100% | 3 | Search CYTOPLASMIC+RNA+VECTOR | Search CYTOPLASMIC+RNA+VECTOR |
7 | INACTIVATED SENDAI VIRUS HVJ E | 420212 | 1% | 100% | 3 | Search INACTIVATED+SENDAI+VIRUS+HVJ+E | Search INACTIVATED+SENDAI+VIRUS+HVJ+E |
8 | SENDAI VIRUS VECTOR | 403725 | 3% | 41% | 7 | Search SENDAI+VIRUS+VECTOR | Search SENDAI+VIRUS+VECTOR |
9 | FUBP1 | 389081 | 2% | 56% | 5 | Search FUBP1 | Search FUBP1 |
10 | FUSE BINDING PROTEIN | 373519 | 2% | 67% | 4 | Search FUSE+BINDING+PROTEIN | Search FUSE+BINDING+PROTEIN |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DUAN, JY , BAO, X , MA, X , ZHANG, Y , NI, D , WANG, HF , ZHANG, F , DU, QS , FAN, Y , CHEN, JW , ET AL (2017) UPREGULATION OF FAR UPSTREAM ELEMENT-BINDING PROTEIN 1 (FUBP1) PROMOTES TUMOR PROLIFERATION AND TUMORIGENESIS OF CLEAR CELL RENAL CELL CARCINOMA.PLOS ONE. VOL. 12. ISSUE 1. P. - | 29 | 53% | 0 |
2 | ZHOU, WX , CHUNG, YJ , CASTELLAR, ERP , ZHENG, Y , CHUNG, HJ , BANDLE, R , LIU, JH , TESSAROLLO, L , BATCHELOR, E , APLAN, PD , ET AL (2016) FAR UPSTREAM ELEMENT BINDING PROTEIN PLAYS A CRUCIAL ROLE IN EMBRYONIC DEVELOPMENT, HEMATOPOIESIS, AND STABILIZING MYC EXPRESSION LEVELS.AMERICAN JOURNAL OF PATHOLOGY. VOL. 186. ISSUE 3. P. 701 -715 | 28 | 54% | 0 |
3 | MATSUSHITA, K , SHIMADA, H , UEDA, Y , INOUE, M , HASEGAWA, M , TOMONAGA, T , MATSUBARA, H , NOMURA, F , (2014) NON-TRANSMISSIBLE SENDAI VIRUS VECTOR ENCODING C-MYC SUPPRESSOR FBP-INTERACTING REPRESSOR FOR CANCER THERAPY.WORLD JOURNAL OF GASTROENTEROLOGY. VOL. 20. ISSUE 15. P. 4316-4328 | 21 | 60% | 2 |
4 | ZHANG, J , CHEN, QM , (2013) FAR UPSTREAM ELEMENT BINDING PROTEIN 1: A COMMANDER OF TRANSCRIPTION, TRANSLATION AND BEYOND.ONCOGENE. VOL. 32. ISSUE 24. P. 2907 -2916 | 31 | 33% | 26 |
5 | HSIAO, HH , NATH, A , LIN, CY , FOLTA-STOGNIEW, EJ , RHOADES, E , BRADDOCK, DT , (2010) QUANTITATIVE CHARACTERIZATION OF THE INTERACTIONS AMONG C-MYC TRANSCRIPTIONAL REGULATORS FUSE, FBP, AND FIR.BIOCHEMISTRY. VOL. 49. ISSUE 22. P. 4620-4634 | 22 | 42% | 20 |
6 | TANAKA, N , ARAKI, K , MIZOKAMI, D , MIYAGAWA, Y , YAMASHITA, T , TOMIFUJI, M , UEDA, Y , INOUE, M , MATSUSHITA, K , NOMURA, F , ET AL (2015) SENDAI VIRUS-MEDIATED GENE TRANSFER OF THE C-MYC SUPPRESSOR FAR-UPSTREAM ELEMENT-BINDING PROTEIN-INTERACTING REPRESSOR SUPPRESSES HEAD AND NECK CANCER.GENE THERAPY. VOL. 22. ISSUE 4. P. 297 -304 | 17 | 46% | 1 |
7 | HAUCK, S , HIESINGER, K , HOSSEINI, SK , ACHENBACH, J , BIONDI, RM , PROSCHAK, E , ZORNIG, M , ODADZIC, D , (2016) PYRAZOLO[1,5A]PYRIMIDINES AS A NEW CLASS OF FUSE BINDING PROTEIN 1 (FUSP1) INHIBITORS.BIOORGANIC & MEDICINAL CHEMISTRY. VOL. 24. ISSUE 22. P. 5717 -5729 | 14 | 54% | 0 |
8 | MATVEEVA, OV , KOCHNEVA, GV , NETESOV, SV , ONIKIENKO, SB , CHUMAKOV, PM , (2015) MECHANISMS OF ONCOLYSIS BY PARAMYXOVIRUS SENDAI.ACTA NATURAE. VOL. 7. ISSUE 2. P. 6 -16 | 21 | 33% | 1 |
9 | MIZOKAMI, D , ARAKI, K , TANAKA, N , SUZUKI, H , TOMIFUJI, M , YAMASHITA, T , UEDA, Y , SHIMADA, H , MATSUSHITA, K , SHIOTANI, A , (2015) GENE THERAPY OF C-MYC SUPPRESSOR FUSE-BINDING PROTEIN-INTERACTING REPRESSOR BY SENDAI VIRUS DELIVERY PREVENTS TRACHEAL STENOSIS.PLOS ONE. VOL. 10. ISSUE 1. P. - | 15 | 41% | 2 |
10 | KINOH, H , INOUE, M , (2008) NEW CANCER THERAPY USING GENETICALLY-ENGINEERED ONCOLYTIC SENDAI VIRUS VECTOR.FRONTIERS IN BIOSCIENCE-LANDMARK. VOL. 13. ISSUE . P. 2327 -2334 | 12 | 55% | 14 |
Classes with closest relation at Level 1 |